Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending February 2014. The report serves as a notification of transactions involving directors and persons discharging managerial responsibilities (PDMRs) regarding the GlaxoSmithKline Deferred Annual Bonus Plan (DABP).
Key Financial Metrics
The filing text does not provide revenue, profit, cash flow, margins, debt, or liquidity figures. The only financial data disclosed relates to the valuation of American Depositary Shares (ADS) for tax withholding purposes:
- ADS Fair Market Value: $55.69 per ADS
Material Changes
The filing details the vesting of pre-tax awards granted under the 2009 DABP on February 24, 2014 (the third anniversary of the award date). Consequently, ADSs were withheld to meet tax liabilities for the following individuals:
| Individual | Role | ADSs Withheld |
|---|---|---|
| Dr. M. Slaoui | Executive Director | 13,774 |
| Ms. D. Connelly | PDMR | 1,991 |
| Mr. D. Troy | PDMR | 5,183 |
Guidance, Outlook, and Risks
The filing text does not contain management commentary, financial guidance, outlook, risk factors, contingencies, or unusual items. The document is strictly a regulatory notification of share transactions.
Investor Verification Checklist
- Verify the vesting schedule and terms of the 2009 Deferred Annual Bonus Plan.
- Confirm the total number of ADSs held by Dr. M. Slaoui, Ms. D. Connelly, and Mr. D. Troy post-withholding.
- Review the company's broader compensation policies regarding tax withholding on equity awards.